Publication:
Correction to: Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study (BMC Cancer, (2021), 21, 1, (1021), 10.1186/s12885-021-08738-z)

Simple item page
dc.contributor.authorMustafa Ermanen_US
dc.contributor.authorBivas Biswasen_US
dc.contributor.authorPongwut Danchaivijitren_US
dc.contributor.authorLingwu Chenen_US
dc.contributor.authorYoke Fui Wongen_US
dc.contributor.authorTarek Hashemen_US
dc.contributor.authorChun Sen Limen_US
dc.contributor.authorBulent Karabuluten_US
dc.contributor.authorHsiao Jen Chungen_US
dc.contributor.authorChandrasekhar Chikatapuen_US
dc.contributor.authorSara Inglesen_US
dc.contributor.authorKhemaies Slimaneen_US
dc.contributor.authorRavindran Kanesvaranen_US
dc.contributor.otherSiriraj Hospitalen_US
dc.contributor.otherNational Yang Ming Chiao Tung Universityen_US
dc.contributor.otherThe First Affiliated Hospital, Sun Yat-sen Universityen_US
dc.contributor.otherNational Cancer Centre, Singaporeen_US
dc.contributor.otherEge Üniversitesien_US
dc.contributor.otherHacettepe Üniversitesien_US
dc.contributor.otherNovartis Pharma S.A.S.en_US
dc.contributor.otherNovartis International AGen_US
dc.contributor.otherMedical Oncologyen_US
dc.contributor.otherRadiotherapy and Oncologyen_US
dc.contributor.otherMedical Oncologyen_US
dc.contributor.otherNovartis Healthcare Pvt. Ltd.en_US
dc.contributor.otherHospital Sultan Ismailen_US
dc.date.accessioned2022-08-04T08:02:59Z
dc.date.available2022-08-04T08:02:59Z
dc.date.issued2021-12-01en_US
dc.description.abstractFollowing publication of the original article [1], the authors identified an error in the author names of Mustafa Erman, Bivas Biswas, Pongwut Danchaivijitr, Lingwu Chen and Chandrasekhar Chikatapu. The given names and family names were erroneously transposed. Further to this, figure 1 has been updated. The line colors in “C” section for “Poor” and “Unknown” have been changed to align with Figure B and legend to match the line colors. The author group has been updated above and the original article [1] has been corrected.en_US
dc.identifier.citationBMC Cancer. Vol.21, No.1 (2021)en_US
dc.identifier.doi10.1186/s12885-021-08848-8en_US
dc.identifier.issn14712407en_US
dc.identifier.other2-s2.0-85118981336en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/75908
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85118981336&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectMedicineen_US
dc.titleCorrection to: Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study (BMC Cancer, (2021), 21, 1, (1021), 10.1186/s12885-021-08738-z)en_US
dc.typeErratumen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85118981336&origin=inwarden_US

Files

Collections

Scopus 2021